BridgeBio Pharma, Inc. Additional Paid in Capital, Common Stock
BridgeBio Pharma, Inc. (BBIO) had Additional Paid in Capital, Common Stock of $1.98 billion as of 2025-06-30, per its 10-Q filed 2025-08-05.
Financial Statements › Balance Sheet › Equity › Equity, Including Portion Attributable to Noncontrolling Interest › Equity, Attributable to Parent › Additional Paid in Capital
us-gaap:AdditionalPaidInCapitalCommonStock · last filed 2025-08-05
- 2025-06-30: Additional Paid in Capital, Common Stock $1.98B.
- 2025-03-31: Additional Paid in Capital, Common Stock $1.94B.
- 2024-12-31: Additional Paid in Capital, Common Stock $1.90B.
- 2024-09-30: Additional Paid in Capital, Common Stock $1.88B.
| Period end | Additional Paid in Capital, Common Stock | Additional Paid in Capital, Common Stock as first filed |
|---|---|---|
| 2025-06-30 | $1.98B 10-Q · filed 2025-08-05 | |
| 2025-03-31 | $1.94B 10-Q · filed 2025-04-29 | |
| 2024-12-31 | $1.90B 10-Q · filed 2025-08-05 | |
| 2024-09-30 | $1.88B 10-Q · filed 2024-11-12 | |
| 2024-06-30 | $1.85B 10-Q · filed 2024-08-01 | |
| 2024-03-31 | $1.82B 10-Q · filed 2024-05-02 | |
| 2023-12-31 | $1.48B 10-K · filed 2025-02-20 | |
| 2023-09-30 | $1.46B 10-Q · filed 2023-11-02 | |
| 2023-06-30 | $1.13B 10-Q · filed 2023-08-03 | |
| 2023-03-31 | $1.11B 10-Q · filed 2023-05-04 | |
| 2022-12-31 | $938.70M 10-K · filed 2024-02-22 | |
| 2022-09-30 | $917.33M 10-Q · filed 2022-11-03 | |
| 2022-06-30 | $892.96M 10-Q · filed 2022-08-04 | |
| 2022-03-31 | $867.60M 10-Q · filed 2022-05-05 | |
| 2021-12-31 | $841.53M 10-K · filed 2023-02-23 | |
| 2021-09-30 | $821.22M 10-Q · filed 2021-11-04 | |
| 2021-06-30 | $799.68M 10-Q · filed 2021-08-05 | |
| 2021-03-31 | $767.12M 10-Q · filed 2021-05-06 | |
| 2021-01-01 | $853.27M 10-K · filed 2022-02-25 | |
| 2020-12-31 | $1.02B 10-K · filed 2022-02-25 | |
| 2020-09-30 | $1.01B 10-Q · filed 2020-11-05 | |
| 2020-06-30 | $992.69M 10-Q · filed 2020-08-11 | |
| 2020-03-31 | $986.75M 10-Q · filed 2020-05-14 | |
| 2019-12-31 | $848.11M 10-K · filed 2021-02-25 | |
| 2019-09-30 | $826.06M 10-Q · filed 2019-11-08 | |
| 2019-06-30 | $469.43M 10-Q · filed 2020-08-11 | $69.00K 10-Q · filed 2019-08-14 |
| 2019-03-31 | $492.68M 10-Q · filed 2020-05-14 | |
| 2018-12-31 | $494.23M 10-K · filed 2020-03-03 | |
| 2017-12-31 | $134.50M 10-K · filed 2020-03-03 | |
| 2016-12-31 | $33.00M 10-K · filed 2020-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |